Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Capital Expenditures (2016 - 2022)

Aptevo Therapeutics (APVO) has disclosed Capital Expenditures for 7 consecutive years, with $4000.0 as the latest value for Q3 2022.

  • Quarterly Capital Expenditures fell 69.23% to $4000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $135000.0 through Dec 2022, down 81.07% year-over-year, with the annual reading at $29000.0 for FY2022, 95.93% down from the prior year.
  • Capital Expenditures hit $4000.0 in Q3 2022 for Aptevo Therapeutics, down from $118000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $927000.0 in Q3 2018 to a low of $4000.0 in Q3 2022.
  • Historically, Capital Expenditures has averaged $315222.2 across 4 years, with a median of $191000.0 in 2021.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 586.67% in 2018 and later crashed 69.23% in 2022.
  • Year by year, Capital Expenditures stood at $927000.0 in 2018, then plummeted by 83.5% to $153000.0 in 2019, then dropped by 22.88% to $118000.0 in 2021, then tumbled by 96.61% to $4000.0 in 2022.
  • Business Quant data shows Capital Expenditures for APVO at $4000.0 in Q3 2022, $118000.0 in Q4 2021, and $13000.0 in Q3 2021.